Dental News - Dentognostics and QIAGEN confirm new partnership deal

Search Dental Tribune

Dentognostics and QIAGEN confirm new partnership deal

A recent deal between dentognostics and QIAGEN is aimed at improving detection of inflammatory processes around dental implants. (Photograph: Atstock Productions/Shutterstock)

Thu. 9. November 2017

save

JENA, Germany: Germany-based companies dentognostics and QIAGEN Lake Constance have recently entered into a partnership to enable use of the ImplantSafe test with the new QIAGEN aLF Reader diagnostic device. Aimed at identification of peri-implantitis, this combination detects subclinical inflammatory processes in their earliest stages by the quantitative assessment of the collagen-destroying enzyme aMMP-8 chairside directly on the patient.

“Dentognostics is excited to be bringing our ImplantSafe test, an aMMP8-based assay, to market exclusively with QIAGEN’s aLF Reader,” said Dirk-Rolf Gieselmann, Chairman of the Dentognostic Group.

Both companies believe the new method supplements clinical diagnosis such as the periodontal screening index and bleeding on probing (BOP) by identifying important immunological elements of subclinical collagen breakdown, which are not detectable in their early phase by radiography or probing. The sensitivity of the new method is between 75 and 95 per cent, up to three times more sensitive than BOP.

“QIAGEN is delighted to team with Dentognostics to bring its dental ImplantSafeDR immunoassay and our aLF lateral flow reader to dentists and their patients across the EU,” said Michael Doumanas, head of sales and marketing at QIAGEN Point-of-Need Systems.

With approximately 4 million affected implant patients in Germany alone, the sustainability of the replacement tooth could now be supported by an implant through the use of the dentognostics test in conjunction with QIAGEN’s reader.

“Together, the ImplantSafeDR test and aLF reader enable dentists to detect periimplantitis in its earliest stages to better protect dental implants. We look forward to continuing to work with Dentognostics to bring this important, new method to market, which will directly benefit dentists and their patients,” said Doumanas.

Interested parties can view the new technology at MEDICA 2017 from 13 to 16 November in Düsseldorf in Germany.

Tags:
To post a reply please login or register
advertisement
advertisement